FDA approves third over-the-counter opioid overdose nasal spray

FDA Approves 4 Mg Rextovy as Third Over-the-Counter Naloxone Product

The Food and Drug Administration has granted over-the-counter (OTC) approval to Rextovy, a 4 mg naloxone nasal spray product manufactured by Amphastar Pharmaceuticals. The agency announced its decision June 16, nearly three years after its last OTC naloxone approval. Rextovy is the third naloxone product to switch from prescription to OTC, a move that will help incrementally lower the retail price of a medication that should be available to the …

Trump FDA Tackles Opioid Crisis With New Medication Approval

The Food and Drug Administration approved a new over-the-counter naloxone nasal spray on Tuesday in an effort to combat the nation's opioid overdose crisis.

FDA approves new OTC overdose-reversing nasal spray

The FDA has approved Rextovy, a 4-milligram naloxone nasal spray that can be purchased without a prescription to reverse opioid overdoses, which could help lower costs and increase access to the medication.

FDA approves third over-the-counter opioid overdose nasal spray

FDA approves third over-the-counter naloxone nasal spray, expanding access and reducing costs for emergency treatment of opioid overdose.

The FDA approves an additional over-the-counter naloxone nasal spray to combat opioid overdoses

Consumers will be able to purchase Rextovy without a prescription at locations including pharmacies, convenience stores and online retailers.

FDA approves third over-the-counter nasal spray to treat opioid drug overdoses

The FDA said the number of overdose deaths has dramatically decreased since it first approved Narcan in 2023, but drug overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl.